By scanning thousands of tissue samples, [ Owkin’s mesothelioma AI program ] was able to help identify new types of patients with mesothelioma and predict which may respond better to certain therapies.
Using whole biopsy slide images taken from nearly 3,000 patients with the aggressive and potentially fatal disease, [ Owkin’s mesothelioma AI program ] was able to pick out novel biological features of the tumor and link them to its overall prognosis.
“Patients with mesothelioma exhibit a very high variability in survival, from a few months to a few years, and this makes it challenging for doctors to plan treatment and to care for these patients,” Owkin CEO Thomas Clozel said in a statement.
“Our research helps to explain the biological causes of this variation and will ultimately lead to the development of more targeted drugs and better management of this terrible disease,” Clozel added.
Known as MesoNet, the program was trained using the French national Mesobank database of tissues and cell lines.[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation
Free. Confidential. No Obligation.